BACKGROUND: Predictive markers can help tailor treatment to the individual in metastatic renal cell carcinoma (mRCC). De Ritis ratio (DRR) is associated with oncologic outcomes in various solid tumors. OBJECTIVE: To assess the value of DRR in prognosticating survival in mRCC patients treated with tyrosine-kinase inhibitors (TKI). METHODS: Overall, 220 mRCC patients treated with TKI first-line therapy were analyzed. An optimal cut-off point for DRR was determined with Youden's J. We used multiple strata for DRR, performed descriptive, Kaplan-Meier and multivariable Cox-regression analyses to assess associations of DRR with progression-free (PFS) and overall survival (OS). RESULTS: Patients above the optimal cut-off point for DRR of ≥ 1.58 had fewer liver metastases (p = 0.01). There was no difference in PFS (p > 0.05) between DRR groups. DRR above the median of 1.08 (HR 1.42; p = 0.03), DRR ≥ 1.1(HR 1.44; p = 0.02), ≥ 1.8 (HR 1.56; p = 0.03), ≥ 1.9 (HR 1.59; p = 0.02) and ≥ 2.0 (HR 1.63; p = 0.047) were associated with worse OS. These associations did not remain after multivariable adjustment. In the intermediate MSKCC group, DRR was associated with inferior OS at cut-offs ≥ 1.0 (HR 1.78; p = 0.02), ≥ 1.1 (HR 1.81; p = 0.01) and above median (HR 1.88; p = 0.007) in multivariable analyses. In patients with clear-cell histology, DRR above median (HR 1.54; p = 0.029) and DRR ≥ 1.1 (HR 1.53; p = 0.029) were associated with OS in multivariable analyses. CONCLUSION: There was no independent association between DRR and survival of mRCC patients treated with TKI in the entire cohort. However, OS of patients with intermediate risk and clear-cell histology were affected by DRR. DRR could be used for tailored decision-making in these subgroups.

Department of Urology 2nd Faculty of Medicine Charles University Prague Czech Republic

Department of Urology Jikei University School of Medicine Tokyo Japan

Department of Urology Medical University of Vienna Vienna Austria

Department of Urology Tabriz University of Medical Sciences Tabriz Iran

Department of Urology University Medical Center Hamburg Eppendorf Martinistraße 52 20246 Hamburg Germany

Department of Urology University of Texas Southwestern Medical Center Dallas TX USA

Department of Urology Weill Cornell Medical School New York NY USA

Institute for Urology and Reproductive Health Sechenov University Moscow Russia

Karl Landsteiner Institute of Urology and Andrology Vienna Austria

Zobrazit více v PubMed

Keizman D, Huang P, Eisenberger MA, Pili R, Kim JJ, Antonarakis ES, et al. Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination. Eur J Cancer. 2011;47(13):1955–1961. doi: 10.1016/j.ejca.2011.04.019. PubMed DOI PMC

Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794–5799. doi: 10.1200/jco.2008.21.4809. PubMed DOI

Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20(1):289–296. doi: 10.1200/jco.2002.20.1.289. PubMed DOI

Rink M, Chun FK, Robinson B, Sun M, Karakiewicz PI, Bensalah K, et al. Tissue-based molecular markers for renal cell carcinoma. Minerva Urol Nefrol. 2011;63(4):293–308. PubMed

Li H, Samawi H, Heng DY. The use of prognostic factors in metastatic renal cell carcinoma. Urol Oncol. 2015;33(12):509–516. doi: 10.1016/j.urolonc.2015.08.003. PubMed DOI

Bensalah K, Montorsi F, Shariat SF. Challenges of cancer biomarker profiling. Eur Urol. 2007;52(6):1601–1609. doi: 10.1016/j.eururo.2007.09.036. PubMed DOI

Ito K, Masunaga A, Tanaka N, Mizuno R, Shirotake S, Yasumizu Y, et al. Impact of inflammatory marker levels one month after the first-line targeted therapy initiation on progression-free survival prediction in patients with metastatic clear cell renal cell carcinoma. Jpn J Clin Oncol. 2019;49(1):69–76. doi: 10.1093/jjco/hyy154. PubMed DOI

Wu J, Chen L, Wang Y, Tan W, Huang Z. Prognostic value of aspartate transaminase to alanine transaminase (De Ritis) ratio in solid tumors: a pooled analysis of 9400 patients. Oncol Targets Ther. 2019;12:5201–5213. doi: 10.2147/OTT.S204403. PubMed DOI PMC

Deritis F, Giusti G, Piccinino F, Cacciatore L. Biochemical laboratory tests in viral hepatitis and other hepatic diseases. Evaluation and follow-uP. Bull World Health Organiz. 1965;32(1):59–72. PubMed PMC

Lee H, Lee SE, Byun SS, Kim HH, Kwak C, Hong SK. De Ritis ratio (aspartate transaminase/alanine transaminase ratio) as a significant prognostic factor after surgical treatment in patients with clear-cell localized renal cell carcinoma: a propensity score-matched study. BJU Int. 2017;119(2):261–267. doi: 10.1111/bju.13545. PubMed DOI

Janisch F, Hillemacher T, Fuehner C, D'Andrea D, Meyer CP, Klotzbücher T, et al. The impact of cytoreductive nephrectomy on survival outcomes in patients treated with tyrosine kinase inhibitors for metastatic renal cell carcinoma in a real-world cohort. Urol Oncol. 2020 doi: 10.1016/j.urolonc.2020.04.033. PubMed DOI

Capitanio U, Cloutier V, Zini L, Isbarn H, Jeldres C, Shariat SF, et al. A critical assessment of the prognostic value of clear cell, papillary and chromophobe histological subtypes in renal cell carcinoma: a population-based study. BJU Int. 2009;103(11):1496–1500. doi: 10.1111/j.1464-410X.2008.08259.x. PubMed DOI

Janisch F, Kienapfel C, Fühner C, Klotzbücher T, Marks P, Hillemacher T et al (2020) Treatment and outcome of metastatic renal cell carcinoma with sarcomatoid differentiation. Currently under review PubMed PMC

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205–216. doi: 10.1093/jnci/92.3.205. PubMed DOI

Schisterman EF, Perkins NJ, Liu A, Bondell H. Optimal cut-point and its corresponding Youden Index to discriminate individuals using pooled blood samples. Epidemiology. 2005;16(1):73–81. doi: 10.1097/01.ede.0000147512.81966.ba. PubMed DOI

Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000;56(2):337–344. doi: 10.1111/j.0006-341x.2000.00337.x. PubMed DOI

Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med. 1989;8(5):551–561. doi: 10.1002/sim.4780080504. PubMed DOI

Kang M, Yu J, Sung HH, Jeon HG, Jeong BC, Park SH, et al. Prognostic impact of the pretreatment aspartate transaminase/alanine transaminase ratio in patients treated with first-line systemic tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma. Int J Urol. 2018;25(6):596–603. doi: 10.1111/iju.13574. PubMed DOI

Kim SH, Park EY, Joo J, Chung J. The De Ritis and neutrophil-to-lymphocyte ratios may aid in the risk assessment of patients with metastatic renal cell carcinoma. J Oncol. 2018;2018:1953571. doi: 10.1155/2018/1953571. PubMed DOI PMC

Ishihara H, Kondo T, Yoshida K, Omae K, Takagi T, Iizuka J, et al. Evaluation of preoperative aspartate transaminase/alanine transaminase ratio as an independent predictive biomarker in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy: a propensity score matching study. Clin Genitourin Cancer. 2017;15(5):598–604. doi: 10.1016/j.clgc.2017.04.011. PubMed DOI

Sekar RR, Patil D, Baum Y, Pearl J, Bausum A, Bilen MA, et al. A novel preoperative inflammatory marker prognostic score in patients with localized and metastatic renal cell carcinoma. Asian J Urol. 2017;4(4):230–238. doi: 10.1016/j.ajur.2017.04.002. PubMed DOI PMC

Sella A, Michaelson MD, Matczak E, Simantov R, Lin X, Figlin RA. Heterogeneity of patients with intermediate-prognosis metastatic renal cell carcinoma treated with sunitinib. Clin Genitourin Cancer. 2017;15(2):291–9.e1. doi: 10.1016/j.clgc.2016.08.013. PubMed DOI

Iacovelli R, De Giorgi U, Galli L, Zucali P, Nole F, Sabbatini R, et al. Is it possible to improve prognostic classification in patients affected by metastatic renal cell carcinoma with an intermediate or poor prognosis? Clin Genitourin Cancer. 2018;16(5):355–9.e1. doi: 10.1016/j.clgc.2018.04.007. PubMed DOI

Bezan A, Mrsic E, Krieger D, Stojakovic T, Pummer K, Zigeuner R, et al. The preoperative AST/ALT (De Ritis) ratio represents a poor prognostic factor in a cohort of patients with nonmetastatic renal cell carcinoma. J Urol. 2015;194(1):30–35. doi: 10.1016/j.juro.2015.01.083. PubMed DOI

Canat L, Ataly HA, Agalarov S, Alkan I, Altunrende F. The effect of AST/ALT (De Ritis) ratio on survival and its relation to tumor histopathological variables in patients with localized renal cell carcinoma. Int Braz J Urol. 2018;44(2):288–295. doi: 10.1590/s1677-5538.Ibju.2017.0173. PubMed DOI PMC

McKay RR, Kroeger N, Xie W, Lee JL, Knox JJ, Bjarnason GA, et al. Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. Eur Urol. 2014;65(3):577–584. doi: 10.1016/j.eururo.2013.08.012. PubMed DOI PMC

Ljungberg B, Albiges L, Bensalah K, Bex A, Giles R, Hora M et al (2019) EAU guideline for renal cell carcinoma. https://uroweb.org/guideline/renal-cell-carcinoma/. Accessed 03/26/2020